Clinical Trials Browser

Phase 3 × Breast Neoplasms × liposomal doxorubicin × Clear all

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06312176 2026-05-22

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Phase 3 Completed

1,925 enrolled 19 charts

Breast Neoplasms

NCT01935492 2020-01-18

Stop&Go

Phase 3 Completed

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Genetic Predisposition to Disease

NCT00266799 2017-06-08

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Phase 3 Completed

210 enrolled 11 charts

Breast Neoplasms

NCT00082095 2014-10-09

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Phase 3 Terminated

Breast Neoplasms

NCT00091442 2014-04-21

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Phase 3 Completed

751 enrolled 10 charts

Breast Neoplasms